In order to overcome hypoxia-induced drug resistance in lung cancer, Fengqiao Li et al. opted for the use of anti-EGFR aptamer [84] to fabricate a multifunctional liposomal complex to co-administrate erlotinib (an EGFR-tyrosine kinase inhibitor) and PFOB (a type of perfluorocarbon (PFC) widely used as a blood substitute for supplying oxygen to the body) to EGFR-overexpressing NSCLC cells (Figure 5f). Here, EGFR is linked to lung cancer.